Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06853015 · ClinicalTrials.gov registry record · Phase 1
Double Dose 4-AP on Functional Recovery After Spinal Cord Injury
A Phase 1 study of SCI - Spinal Cord Injury, sponsored by Shirley Ryan AbilityLab.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
- 1
- Study location
NCT06853015: Recruiting Phase 1 study of SCI - Spinal Cord Injury, sponsored by Shirley Ryan AbilityLab.
NCT06853015 is a Phase 1 study of SCI - Spinal Cord Injury that is actively recruiting participants, run by Shirley Ryan AbilityLab. The registered enrollment target is 27 participants, below the 36-participant average among 13 other SCI - Spinal Cord Injury trials with a reported enrollment target (25% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06853015, a Phase 1 study of SCI - Spinal Cord Injury, is actively recruiting participants, sponsored by Shirley Ryan AbilityLab.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to test a strategy to potentiate functional recovery of lower limb motor function in individuals with spinal cord injury (SCI). The FDA approved drug, Dalfampridine (4-AP). 4-AP will be used twice-daily in combination of Spike-timing-dependent plasticity (STDP) stimulation and STDP stimulation with limb training.
Primary Outcome
Electrical stimulation will be performed placing the cathode on the upper thoracic between the spinal processes between T3 and T4 vertebrae and the anode at \~10 cm above
Conditions Studied
Interventions
- DRUG Placebo
- BEHAVIORAL Exercise training
- DRUG Dalfampridine
- OTHER STDP stimulation
Study Locations (1)
Illinois
- Shirley Ryan Abilitylab - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2025-02-01 |
| Est. Completion | 2026-03 |
| Phase | Phase 1 |
What NCT06853015 shows while recruiting
NCT06853015 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 36-participant average among 13 other SCI - Spinal Cord Injury trials with a reported enrollment target (25% lower).
The record links to 1 condition, with SCI - Spinal Cord Injury appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT06853015 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT06853015 about?
NCT06853015 is a clinical study titled "Double Dose 4-AP on Functional Recovery After Spinal Cord Injury". The purpose of this study is to test a strategy to potentiate functional recovery of lower limb motor function in individuals with spinal cord injury (SCI). The FDA approved drug, Dalfampridine (4-AP). 4-AP will be used twice-daily in combination of Spike-timing-dependent plasticity (STDP) stimulati...
What is the current status of trial NCT06853015?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2025-02-01. Estimated completion is 2026-03.
What conditions does trial NCT06853015 study?
This clinical trial studies the following conditions: SCI - Spinal Cord Injury.
What interventions are being tested in trial NCT06853015?
The interventions under investigation include: Placebo (DRUG), Exercise training (BEHAVIORAL), Dalfampridine (DRUG), STDP stimulation (OTHER).
Who is sponsoring clinical trial NCT06853015?
This trial is sponsored by Shirley Ryan AbilityLab, which has 138 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06853015 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for SCI - Spinal Cord Injury
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06853015's enrollment target sits among peer trials
27 8th of 13 higher than 6 of 13 other SCI - Spinal Cord Injury trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other SCI - Spinal Cord Injury trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effects of CBD/CBD-A Oral Extract on Resting-state EEG and Neuropathic Pain Symptoms After SCI
RECRUITING · Phase 1
-
Exploring the Utility of [18F]3F4AP for Demyelination Imaging
RECRUITING · Phase 1
-
The Utilization Effects of Powered Wearable Orthotics in Improving Upper Extremity Function and ADL in Persons With SCI
RECRUITING · NA
-
TPAD for Recovery of Standing After Severe SCI
RECRUITING · NA
-
Safety, Feasibility, and Efficacy of TSCS on Stabilizing Blood Pressure for Acute Inpatients With SCI
RECRUITING · NA
-
Epidural Stimulation After Neurologic Damage: Long-Term Outcomes
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI